"Tirzepatide versus insulin glargine in type 2 diabetes and increased cardiovascular risk (SURPASS-4): a randomised, open-label, parallel-group, multicentre, phase 3 trial." Lancet , 398(10313), 1811-1824
16 GLP-1RAs achieve sustained pharmacological effects by resisting degradation by DPP-4 in the body, consequently contributing to hyperglycemia and insulin resistance related to glucose metabolism, 17,18 lipid profile alterations, changes in fat composition, visceral fat accumulation, and obesity related to lipid metabolism, 1921 which constitute the systemic metabolic characteristics of interest in MASLD management
(2023) NHS [accessed 29 January 2026] Omeprazole
employed a diet-induced obesity (DIO) NASH mouse model as well as ob/ob mice , which were treated with liraglutide, obeticholic acid (a farnesoid-X-receptor [FXR]), or elafibranor (a dual proliferator-activated receptor-a/ [PPAR-/]) for 8 weeks [12]
based popular nutrition supplement brand GNC conducted a first-of-its-kind nutritional analysis of GLP-1 users, revealing widespread deficiencies in essential nutrients and protein intake
Viral gastroenteritis Only one trial was evaluated regarding the risk of viral gastroenteritis in patients receiving GLP-1 RAs
